Higher baseline plaque burden due to lifetime exposure to risk factors (including Lp[a]) might have resulted in increased progression of coronary atherosclerosis, irrespective of Lp(a) levels during the study, and it remains to be determined whether reducing Lp(a) levels in patients with a high plaque burden would further reduce plaque progression. The gene discussed is LPA; the disease is coronary atherosclerosis.